Advanced oxidation protein products downregulate CYP1A2 and CYP3A4 expression and activity via the NF-κB-mediated signaling pathway in vitro and in vivo

Tianrong Xun1 · Zhufen Lin1 · Xiaokang Wang1 · Xia Zhan1 · Haixing Feng2 · Danna Gan1 · Xixiao Yang1,2

Received: 27 October 2020 / Revised: 22 April 2021 / Accepted: 26 April 2021 / Published online: 24 May 2021
© The Author(s), under exclusive licence to United States and Canadian Academy of Pathology 2021. This article is published with open access

Abstract
Uremic toxin accumulation is one possible reason for alterations in hepatic drug metabolism in patients with chronic kidney disease (CKD). However, the types of uremic toxins and underlying mechanisms are poorly understood. In this study, we report the role of advanced oxidation protein products (AOPPs), a modified protein uremic toxin, in the downregulation of cytochromes P450 1A2 (CYP1A2) and P450 3A4 (CYP3A4) expression levels and activities. We found that AOPP accumulation in plasma in a rat CKD model was associated with decreased protein levels of CYP1A2 and CYP3A4. CYP1A2 and CYP3A4 metabolites (acetaminophen and 6β-hydroxytestosterone, respectively,) in liver microsomes were also significantly decreased. In human hepatocytes, AOPPs significantly decreased CYP1A2 and CYP3A4 protein levels in a dose- and time-dependent manner and downregulated their activities; however, bovine serum albumin (BSA), a synthetic precursor of AOPPs, had no effect on these parameters. The effect of AOPPs was associated with upregulation of p-IKKα/β, p-IκBα, p-NF-κB, and inflammatory cytokines protein levels and increases in p-IKKα/β/IκKα, p-IκBα/IκBα, and p-NF-κB/NF-κB phosphorylation ratios. Further, NF-κB pathway inhibitors BAY-117082 and PDTC abolished the downregulatory effects of AOPPs. These findings suggest that AOPPs downregulate CYP1A2 and CYP3A4 expression and activities by increasing inflammatory cytokine production and stimulating NF-κB-mediated signaling. Protein uremic toxins, such as AOPPs, may modify the nonrenal clearance of drugs in patients with CKD by influencing metabolic enzymes.

Introduction
Patients with chronic kidney disease (CKD) require a mean of 14.2 concurrent drugs to manage their complications and associated comorbidities, and overdose or underdose errors account for 20.4% of all medical problems in these patients [1]. Dosing alterations for many renally cleared drugs in CKD patients have been well characterized; however, hepatic metabolism is also altered in CKD [2]. Drug pharmacokinetics are the result of the coordinated action of various drug-metabolizing enzymes, including cytochromes P450 (CYPs), and this coordinated action is highly altered in CKD [3]. These alterations are poorly understood, but numerous animal studies have indicated that CKD and decreased hepatic metabolism (including metabolism involving CYPs) are closely associated [4]. Moreover, CYPs activity is reduced in patients with CKD [5, 6].

CYP3A4 is the main CYP3A family member and is responsible for the metabolism of ~50% of clinically used drugs. Many of these drugs are used to treat CKD or its comorbidities [7, 8]. Alterations in the pharmacokinetics of CYP1A2-metabolized drugs have been reported in CKD [3]. Studies on uremic serum collected from patients with end-stage renal disease (ESRD) have indicated that ESRD decreases the protein expression and activities of the major xenobiotic-metabolizing CYP1A and CYP3A families in rat hepatocytes [9, 10]. Furthermore, intravenously administering a CYP3A4 substrate led to 6-fold higher systemic exposure in patients with ESRD compared to healthy controls [11]. Thus, the activities of CYP1A2 and CYP3A4 are decreased in CKD and are expected to have significant
clinical implications, with altered drug pharmacokinetics and increased adverse drug events in patients with CKD. However, specific CKD-related factors that downregulate the activities of CYP1A2 and CYP3A4 have not been identified. Uremic toxins, which accumulate in the body in patients with CKD, may be involved [12, 13]. Nevertheless, the underlying molecular mechanism remains unknown.

AOPPs are a family of dityrosine-containing protein products that have been detected in the plasma of chronic uremic patients [14]. AOPPs are novel oxidative stress biomarkers and proinflammatory mediators and are related to oxidation-associated diseases [15]. AOPPs are high-affinity ligands for RAGE and CD36 and increase inflammatory cytokine (IL-6 and TNF-α) production and oxidant-dependent activation of the NF-κB signaling pathway in human chondrocytes [16, 17]. AOPPs have been studied extensively from their structural and pharmacokinetic properties to their clinical significance.

The NF-κB signaling pathway plays a key role in the regulation of the inflammatory cytokine production and NF-κB binds to CYP450 promoter regions to regulate CYP450 transcription and translation [18]. Activation of the NF-κB pathway is mediated by an increase in the phosphorylation of IKK and interaction with the inhibitory protein inhibitor κB (IκB) that binds to NF-κB and sequesters it in the cytoplasm. Upon stimulation with exogenous substances, IκB is phosphorylated by IκB kinases and then degraded by the proteasome. This prevents IκB from sequestering NF-κB in the cytoplasm and leads to NK-κB translocation to the nucleus and activation or silencing of its target genes [19, 20]. We hypothesized that AOPPs increase inflammatory cytokine production and activate the NF-κB signaling pathway, thereby regulating drug metabolism.

The objective of this study was to determine whether AOPPs can modify the expression of CYP1A2 and CYP3A4 and whether inflammatory cytokines and the NF-κB signaling pathway are involved in this process. To address this issue, we utilized a rat model of CKD to investigate the effect of AOPPs on CYP1A2 and CYP3A4 expression and activities in the liver. Thereafter, AOPPs-mediated downregulation of CYP1A2 and CYP3A4 was investigated in HepG2 and L-02 cells. Finally, we suggest a molecular mechanism by which AOPPs downregulate CYP1A2 and CYP3A4 expression and activity.

Materials and methods

Chemicals and reagents

BAY-117082, pyrrolidine dithiocarbamate (PDTC), 4’,6-diamidino-2-phenylindole (DAPI) and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Clorox was purchased from Macklin (Shanghai, China). Polyvinylidene fluoride (PVDF) membranes and a western blot detection system were purchased from Millipore (Darmstadt, Germany). Primary antibodies against CYP1A2 (DF3565), CYP3A4 (DF7001), histone H3 (AF0863), and GAPDH (AF7021) were purchased from Affinity Biosciences (California, USA). Primary antibodies against NF-κB (8242), p-NF-κB (3039), IKKβ (4812), p-IκBα (5209), IKKα (2682), p-IκKα/β (2697), and horse-radish peroxidase-conjugated goat anti-mouse (7076 S) and goat anti-rabbit (7074 S) IgG were purchased from Cell Signaling Technology (Beverly, MA, USA). Tris-buffered saline with Tween 20 (TBST), antibody dilution buffer, and a pNF-κB-luc reporter plasmid were purchased from Beyotime (Shanghai, China).

Preparation of AOPPs

AOPPs were prepared in vitro as described previously [21]. Briefly, 20 mg/ml BSA solution was combined with 40 mmol/L Clorox at a molar ratio of 1:140 for 30 min at room temperature protected from light. The samples were then dialyzed overnight against phosphate-buffered saline (PBS) to remove the free Clorox. Endotoxin levels in AOPP solutions were determined using an Amebocyte lysate assay kit (T-125; Zhanjiang, China). BSA dissolved in PBS was used as control.

Animal model

All animal studies were approved by the institutional Animal Experiment Committee of the Southern Medical University (Guangzhou, China). A total of 39 male Sprague–Dawley rats (160–200 g) were obtained from the Southern Medical University Animal Experiment Center (Guangzhou, China). The rats were treated according to a two-step procedure as described previously [22]. Briefly, the rats underwent five-sixths nephrectomy (5/6 nx; n = 21 (3 later excluded due to surgery-related death) or sham operation (sham; n = 18). Two weeks later, the 5/6 nx and sham rats were randomized into subgroups (groups 1–3; 5/6 nx, and sham groups 4–6; n = 6 per group). The rats in received intraperitoneal injections as follows once every other day for 8 weeks: (1) PBS (groups 1 and 4), (2) unmodified BSA (30 mg/kg, groups 2 and 5), and (3) AOPPs (30 mg/kg, groups 3 and 6). After 8 weeks, the rats were anesthetized with 3% pentobarbital sodium (v/v), and plasma samples were collected. The left kidney, the liver and the intestine were collected in liquid nitrogen.

AOPPs concentration determination

The concentration of AOPPs in the rat plasma was determined by spectral analysis as described previously [14].
Aliquots of 200 µl of chloramine-T for calibration (0–100 µmol), 200 µl of serum samples (diluted 1:5 in PBS), and 200 µl of PBS as a blank control were placed in a 96-well plate. Subsequently, 10 µl of 1.16 M potassium iodide and 20 µl of acetic acid were added to each well. The absorbance of the reaction system at 340 nm was immediately measured. The AOPPs concentration was expressed as micromoles of chloramine-T equivalents per liter. The AOPPs concentration divided by the albumin level was regarded as the AOPPs level.

**Western blotting**

Cultured HepG2 and L-02 cells or frozen rat liver tissue samples were lysed with radioimmunoprecipitation assay (RIPA) lysis buffer containing protease inhibitors. The cytoplasmic and nuclear proteins were extracted with a nuclear and cytoplasmic protein extraction kit (KGP150; KeyGEN BioTECH, Jiangsu, China) according to the manufacturer’s instructions. Equal amounts of protein were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (PAGE) using 10% acrylamide gels and then transferred to polyvinylidene fluoride (PVDF) membranes. The membranes were incubated with the following primary antibodies overnight at 4 °C: CYP1A2 (1:500), CYP3A4 (1:500), GAPDH (1:1000), NF-κB (1:1000), p-NF-κB (1:1000), IkBα (1:1000), p-IkBα (1:1000), IKKα (1:1000), p-IKKα/β (1:1000), and histone H3 (1:1000; used as a reference antibody for nuclear proteins). The membranes were washed with TBST and incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:3,000) or goat anti-mouse IgG (1:3000) for 1 h at room temperature. The signals were visualized using enhanced chemiluminescence (ECL) detection, and a densitometric analysis was performed using imaging software. The protein levels were normalized to GAPDH or histone H3.

**Hepatic microsome isolation**

Hepatic microsomes were isolated by standard differential centrifugation procedures as previously described with a minor modification [23]. In brief, liver tissue was perfused with prechilled buffer comprising 1.5 mM EDTA, 1 mM DTT, 8 mM KH2PO4, 0.28 mM PMSF, and 5.6 mM Na2HPO4. Thereafter, the collected tissue was shredded and homogenized in 50 mM buffer (pH = 7.4) comprising 1 mM EDTA, 0.28 mM PMSF, and 250 mM sucrose. The mixture was centrifuged at 12,000 × g for 15 min and the sediment was discarded. Next, the supernatant was centrifuged at 35,000 × g and 4 °C for 1 h. The microsomes were resuspended in 250 mM sucrose and the mixture was immediately stored at −80 °C. The concentration of hepatic microsomes was determined using a bicinchoninic acid (BCA) protein assay kit (KGSK4051; KeyGEN BioTECH, Jiangsu, China).

**Metabolism of CYP1A2 and CYP3A4 substrates**

The metabolic activities of CYP1A2 and CYP3A4 in hepatic microsomes was determined using specific probe substrates. Phenacetin was used as a probe for CYP1A2 [24] and testosterone was used as a probe for CYP3A4 [25]. Briefly, microsomes (0.4 mg/ml) were mixed on ice with 50 mM buffer (pH = 7.4) comprising 1.5 mM EDTA, 1 mM DTT, 8 mM KH2PO4, 0.28 mM PMSF, and 5.6 mM Na2HPO4, substrate, and a NADPH-generating system in a final incubation volume of 250 µl. The mixture was incubated in a shaking water bath at 37 °C for 30 min. The reaction was terminated by adding 200 µl of cold methanol and the mixture was centrifuged at 15,000 × g for 30 min. The supernatant was collected in a glass injection bottle.

Acetaminophen and 6β-hydroxytestosterone was assessed by high-performance liquid chromatography (HPLC) system (Shimadzu, Japan) with an Eclipse Plus C18 column (5 μm, 4.6 × 250 mm; Agilent). A sample volume of 20 µl was injected into the column. The sample rack and column were maintained at 30 °C and the flow rate was maintained at 0.75 ml/min. Mobile phase A was HPLC-grade water with 0.1% (v/v) formic acid, and mobile phase B was 100% acetonitrile. An ultraviolet detector was used to detect acetaminophen (257 nm) and 6β-hydroxytestosterone (245 nm). The quantification of acetaminophen and 6β-hydroxytestosterone was based on the peak area.

**Immunofluorescence staining**

Immunofluorescence staining was performed using an NF-κB activation and nuclear translocation assay kit (SN368; Beyotime) according to the manufacturer’s instructions with minor modifications. In brief, fixed cells were blocked with a sealing fluid for 1 h at room temperature. The cells were then incubated with rabbit anti-NF-κB antibody overnight at 4 °C. After incubation with Cy5-conjugated anti-rabbit IgG for 1 h, the nuclei were stained with DAPI (1 µg/ml). Fluorescent signals were captured with an FluoView FV10i self-contained confocal laser scanning microscope (Olympus, USA).

**Transient transfection and reporter gene assay**

A total of 0.5 µg of pNF-κB-luc reporter plasmid or the equivalent amount of a control plasmid (D2206; Beyotime) was transfected into cells using Lipofectamine 3000 reagent (1741089; Life Technologies, Waltham, MA, USA) according to the manufacturer’s protocol. After transfection for 24 h, the cells were treated with AOPPs or without AOPPs (CON). Thereafter, cell lysis was carried out using
reporter lysis buffer (RG055M; Beyotime). The cell extract was mixed with a luciferase substrate and the luciferase activity was immediately determined using a luminometer microplate reader (Spectrometer MD5; XYZ, USA).

**Enzyme linked immunosorbent assay (ELISA)**

After coculture with AOPPs, the concentrations of proinflammatory cytokines were measured in supernatants prepared using plasma or macrophages from the rats subjected to various treatments. The levels of TNF-α and IL-6 in the supernatants were detected using ELISA kits (RA20035 and RA20607; Bio-Swamp, China) according to the manufacturer's instructions.

**Statistical analysis**

The data are expressed as mean ± standard deviation (SD). A Michaelis–Menten model was used to fit the data regarding phenacetin and testosterone metabolite formation. The statistical analyses were performed in GraphPad Prism software (GraphPad 5.0 Software, USA). The data were analyzed using Student's *t* test or one-way analysis of variance (ANOVA), with the least significant difference test being used as the post-hoc test. The data were also analyzed using three-factor ANOVA. Differences were considered statistically significant at *p* < 0.05.

**Results**

**AOPPs administration increased AOPPs accumulation in plasma**

In the CKD model, renal function parameters, including plasma creatinine (Cr) (Fig. 1A), blood urea nitrogen (BUN) (Fig. 1B) and AOPPs (Fig. 1C), were increased by 1.9-fold, 7.3-fold, and 2.0-fold compared with those in the sham group. After AOPPs administration, AOPPs were increased in the sham and 5/6 nx groups (Fig.1D), 2.6-fold and 1.6-fold compared with that in the PBS group. These data suggest that AOPPs administration increases AOPPs accumulation in the plasma.

**AOPPs downregulated CYP1A2 and CYP3A4 protein levels in the intestine, kidney, and liver**

In the sham group, treatment with AOPPs reduced CYP1A2 protein levels in the intestine, kidney, and liver by 44%, 28%, and 35%; CYP3A4 protein levels in the intestine, kidney, and liver were reduced by 46%, 42%, and 40%, respectively (Fig. 2A). In the 5/6 nx group treated with AOPPs, CYP1A2 protein levels in the intestine, kidney, and liver were reduced by 59%, 63%, and 66% and CYP3A4 protein levels were reduced by 71%, 71%, and 68%, respectively, compared with those in the PBS or BSA groups (Fig. 2B).

**AOPPs downregulated the activities of CYP1A2 and CYP3A4 in the liver**

The activities of CYP1A2 (Fig. 2E) and CYP3A4 (Fig. 2F) in the liver microsomes were evaluated using phenacetin and testosterone, respectively. After treatment with AOPPs, the *V*ₘₐₓ values for acetaminophen in the sham and 5/6 nx groups were reduced by 57% and 49% and the *K*ₘ values were reduced by 52% and 64%, respectively. The values of *V*ₘₐₓ for 6β-hydroxytestosterone in the AOPP-treated sham and 5/6 nx rats were reduced by 31% and 43%, respectively; the values of *K*ₘ were reduced by 27% and 42%, respectively, compared with those in the PBS or BSA groups.

**AOPPs downregulated CYP1A2 and CYP3A4 protein levels in HepG2 and L-02 cells**

CYP1A2 and CYP3A4 protein levels in HepG2 and L-02 cells were gradually decreased concomitant to an increase in the AOPPs concentrations (Fig. 3A). After treatment with 100 µg/ml AOPPs, CYP1A2 protein levels in HepG2 and L-02 cells were reduced by 28% and 49% and the CYP3A4 levels were reduced by 25% and 23%, respectively. After treatment with 200 µg/ml AOPP, CYP1A2 protein levels in HepG2 and L-02 cells were reduced by 53% and 60% and the CYP3A4 levels were reduced by 57% and 44%, respectively. CYP1A2 and CYP3A4 protein levels in HepG2 and L-02 cells were gradually decreased over time (Fig. 3B). After treatment with 200 µg/ml AOPPs for 24 h, CYP1A2 protein levels in HepG2 and L-02 cells were gradually decreased over time (Fig. 3B). After treatment with 200 µg/ml AOPPs for 24 h, CYP1A2 and CYP3A4 protein levels in HepG2 and L-02 cells were reduced by 61% and 49% and the CYP3A4 levels were reduced by 52% and 33%, respectively. In summary, CYP1A2 and CYP3A4 levels were lower when the concentrations of AOPPs exceeded 100 µg/ml or when the incubation time reached 24 h.

**AOPPs downregulated CYP1A2 and CYP3A4 activities in the liver microsomes**

AOPPs inhibited the production of acetaminophen (Fig. 3E) and 6β-hydroxytestosterone (Fig. 3F) in the rat liver microsomes in a dose-dependent manner. After treatment with 100 µg/ml AOPPs, the *V*ₘₐₓ values for acetaminophen and 6β-hydroxytestosterone in the microsomes were reduced by 29% and 21%; however, the *K*ₘ values were increased by 6.1-fold and 2.9-fold, respectively. After 200 µg/ml AOPP treatment, the *V*ₘₐₓ values were reduced
by 52% and 41%; however, the $K_m$ values were increased by 6.8-fold and 3.0-fold, respectively.

**AOPPs activated the IKK/IκB/NF-κB pathway in vitro and in vivo**

To investigate the mechanism responsible for the decrease in CYP1A2 and CYP3A4, we investigated the links between IKK/IκB signaling and NF-κB activation. In HepG2 and L-02 cells (Fig. 4A), AOPPs significantly and dose-dependently induced IKK/IκB/NF-κB phosphorylation compared to the CON group. BSA had no effect compared to the CON group. We next examined the effect of AOPPs on the protein expression of IKK/IκB/NF-κB in the liver of rats. AOPPs significantly increased p-IKKα/β, p-IκBα, and p-NF-κB protein levels in the sham and 5/6 nx rats and significantly increased the phosphorylation ratio of p-IKKα/β/IKKα, p-IκBα/IκBα, and p-NF-κB/NF-κB (Fig. 4B).

**AOPPs-induced nuclear translocation of NF-κB**

We assayed the nuclear translocation of the NF-κB protein induced by AOPPs using a confocal microscope. NF-κB protein in the nucleus was increased in HepG2 (Fig. 5A) and L-02 (Fig. 5B) cells, with almost no increase in the control group. NF-κB protein was detected in the cytoplasmic and nuclear protein fractions of HepG2 and L-02 cells, and NF-κB protein levels were slightly increased in the cytoplasm and significantly increased in the nucleus in a dose-dependent manner (Fig. 5C).

**AOPPs downregulated CYP1A2 and CYP3A4 expression via the NF-κB pathway**

To gain an insight into NF-κB activation, we examined the effects of AOPPs on a luciferase reporter construct containing the functional gene followed by the coding sequence.
of the firefly luciferase gene. Similar to lipopolysaccharide, AOPPs can dose-dependently induce NF-κB pathway activation in HepG2 and L-02 cells compared with the CON groups of the corresponding cells, thus increasing the transcription and translation of the luciferase reporter gene (Fig. 6A). Inhibitors of the NF-κB pathway, 5 μM BAY-117082 (Fig. 6B) and 25 μM PDTC (Fig. 6C), effectively ameliorated the decrease in the CYP1A2 and CYP3A4 protein expression levels induced by AOPPs. The protein expression levels in the BAY-117082 (Fig. 6D) and PDTC (Fig. 6E) groups were quantified by the ImageJ software. These data suggest that AOPPs downregulate CYP1A2 and CYP3A4 expression via the NF-κB pathway.

**AOPPs downregulated CYP1A2 and CYP3A4 expression via the inflammatory cytokine pathway**

Initially, the effect of AOPPs administration on the expression of TNF-α and IL-6 in the rat plasma and macrophages was examined by ELISA. After AOPPs administration, the concentrations of TNF-α in the plasma of the sham and 5/6 nx rats were increased by 6.0-fold and 1.3-fold and the levels of IL-6 were increased by 4.6-fold and 1.4-fold, respectively (Fig. 7A). In rat macrophages, AOPPs increased the levels of IL-6 and TNF-α in a dose-dependent manner with no effect of BSA. The levels were significantly higher than that detected in the CON group (Fig. 7B). Next, we found that IL-6 treatment caused a dose-dependent decrease in the protein expression of CYP1A2 and CYP3A4, respectively. Each data point represents the mean of three replicates and the error bars represent standard error of the mean (n = 3). Data are presented as mean ± SD; *p < 0.05 compared with the PBS group. Data were normalized to GAPDH.

**Discussion**

This study demonstrates that AOPPs mediate the down-regulation of CYP1A2 and CYP3A4 in vitro and in vivo. An exogenous increase in the AOPP plasma concentration significantly increased TNF-α and IL-6 release and reduced the expression and metabolic activities of CYP1A2 and CYP3A4 proteins in the liver. In human hepatocytes, purified AOPPs significantly reduced the protein expression of
CYP1A2 and CYP3A4 by activating the relevant proteins in the NF-κB pathway. BAY-117082 and PDTC, inhibitors of the NF-kB pathway, significantly reversed the effect of AOPPs.

A number of studies have shown that CKD alters renal and nonrenal drug elimination; the accumulated uremic toxins and inflammatory cytokines may modulate metabolic enzymes either directly or by inhibiting protein expression [26]. New techniques to remove small-molecule or protein-bound uremic toxins from patients with CKD can still leave these patients with altered drug pharmacokinetics in response to certain drugs, and the pharmacokinetic parameters are difficult to assess [6]. To explore the effects of AOPPs in CKD, we used the 5/6 nx CKD model, in which the residual nephrons are characterized by elevated perfusion, filtration, and pressure, eventually leading to CKD. Markers of CKD are increased in this model by 8 weeks, such as serum creatinine, BUN and AOPPs (Fig. 1A–C). Elevated perfusion and filtration increase the effects of uremic toxins on the liver. However, the 5/6 nx model can limit liver function changes caused by CKD, unlike other CKD models (e.g., the adenine model).

AOPPs, a new class of renal pathogenic mediators of CKD progression that gradually increase in the blood with CKD progression, are dityrosine-containing crosslinking protein products formed during oxidative stress by reactions of plasma proteins with chlorinated oxidants [27]. AOPPs are primarily eliminated in the liver via the scavenger receptors in hepatic non-parenchymal cells and macrophages, and they are involved in liver disease progression via highly complex mechanisms [28]. Although several studies have investigated the profound effects of AOPPs regarding progressive liver function damage, there have only been a few studies on the potential mechanisms [29]. To the best of our knowledge, this study is the first to clarify that AOPPs mediate the downregulation of the expression and activities of CYP1A2 and CYP3A4 in the liver. The plasma AOPP concentration was significantly increased in the AOPPs-treated rats compared to the BSA- or PBS-treated rats, regardless of whether the rats were in the sham or 5/6 nx group (Fig. 1D). The increase plasma levels of significantly decreased the protein expression of the metabolic enzymes CYP1A2 and CYP3A4 in the liver (Fig. 2A, B), and the metabolism of the probe substrates was significantly decreased (Fig. 2E, F). Thus, AOPPs can reduce CYP1A2 and CYP3A4 function in the liver and thereby influence the normal physiological function of the liver.
To further explore the independence of the effect of AOPPs, we cocultured the HepG2 and L-02 cell lines with or without AOPPs to confirm the accuracy of our results. HepG2 cells are transformed human hepatocellular cells that maintain the basic characteristics of hepatocytes and exhibit CYP1A2 and CYP3A4 expression. L-02 cells are normal human hepatocytes that also exhibit CYP1A2 and CYP3A4 expression and can be used as control cells to compare to cancer cells [30, 31]. To confirm that the in vitro AOPPs experiments are relevant to the in vivo experiments, we performed dose- and time-dependent assays of AOPPs effects. In HepG2 or L-02 cells, AOPPs reduced the CYP1A2 and CYP3A4 protein expression in a dose- (Fig. 3A) and time-dependent (Fig. 3B) manner. Liver microsomes are a common model for specific detection of enzyme metabolism in vivo [12]. In this study, the effects of AOPPs on the metabolism of phenacetin (Fig. 3E) and testosterone (Fig. 3F) were explored. Phenacetin is a specific substrate of CYP1A2 and its main metabolite is acetaminophen [24]. Testosterone is a specific substrate of CYP3A4 and its main metabolite is 6β-hydroxytestosterone [25]. Each compound specifically responds to changes in the activity of the corresponding metabolic enzyme [13, 32]. The results of the CYP1A2 and CYP3A4 assays were similar to the in vivo data from rats. However, the marked increases in the $K_m$ values in the liver microsome reaction system may be related to the non-specific binding of AOPPs.

AOPPs can induce reactive oxygen species production and activate the NF-κB pathway to produce a series of
NF-κB plays an important role in mediating the suppression of drug-metabolizing enzymes (DMEs). NF-κB activation has been associated with inflammatory conditions, oxidative stress, and cross-talk with several nuclear receptors that alter the expression and activity of DMEs, thereby influencing drug metabolism. However, it is unclear whether NF-κB activation is involved in the AOPPs-induced decrease in DMEs in the liver. To ascertain the mechanism, we assessed the NF-κB pathway and the associated upstream proteins, including p-IKKα/β, p-IκBα, and p-NF-κB. We found that these upstream proteins were significantly upregulated (Fig. 4). In AOPPs-treated cells transfected with a luciferase reporter plasmid, the luminescence intensity was significantly increased, indicating NF-κB pathway activation (Fig. 6A). At the same time, NF-κB protein was upregulated in the cytoplasm and nucleus, with increased NF-κB protein translocation to the nucleus (Fig. 5A–C). Furthermore, the AOPPs-induced downregulation of CYP1A2 and CYP3A4 expression was significantly ameliorated by BAY-117082.
Fig. 6 AOPPs downregulated CYP1A2 and CYP3A4 expression via the NF-κB pathway. NF-κB-dependent firefly luciferase reporter gene was transfected into HepG2 or L-02 cells, and the reporter gene expression (A). HepG2 or L-02 cells were treated with AOPPs (200 µg/ml) for 48 h and cocultured with BAY-117082 (B) and PDTC (C) to restore the downregulated expression levels of CYP1A2 and CYP3A4. Protein expression levels of CYP1A2 and CYP3A4 were quantified by ImageJ software (D, E). Each experiment was performed with a different isolate. Data are presented as mean ± SD; *p < 0.05 compared with the CON group; †p < 0.05 compared with the group without BAY-117082 or PDTC. Data were normalized to GAPDH.

and PDTC. Thus, we showed that the inhibition of the NF-κB pathway prevented the decrease in the CYP1A2 and CYP3A4 expression. Research on the precise mechanism of AOPPs-induced downregulation of DMEs is ongoing.

We also evaluated whether inflammatory cytokines can directly influence the CYP1A2 and CYP3A4 expression and activity. AOPPs are a key factor in inflammatory diseases and can induce proinflammatory cytokine release [16, 35]. The levels of multiple cytokines are increased in the plasma of patients with CKD [36]. IL-6 and TNF-α influence DME expression in vitro and in vivo [37]. In our rat model, AOPPs increased the IL-6 and TNF-α concentrations in the plasma (Fig. 7A), and they dose-dependently increased the IL-6 and TNF-α release in the rat macrophages (Fig. 7B). This result shows that AOPPs can upregulate the levels of IL-6 and TNF-α, which is consistent with previous findings. After treatment with various concentrations of IL-6 or TNF-α, the protein expression levels of CYP1A2 and CYP3A4 in HepG2 and L-02 (Fig. 7C, D) cells were dose-dependently downregulated. This result indirectly suggests that IL-6 and TNF-α may participate in the AOPPs-related regulation of CYP1A2 and CYP3A4. However, the effects of IL-6 and
TNF-α occur concurrently in vivo and our IL-6 and TNF-α experiments were carried out separately in the in vitro models. Thus, additional experiments are needed to determine these specific interactions.

This study demonstrates that AOPPs significantly decrease the expression and activities of the CYP1A2 and CYP3A4 enzymes via the NF-κB signaling pathway, and IL-6 and/or TNF-α may mediate this process (Fig. 8). To the best of our knowledge, this is the first study to systematically evaluate the effect of AOPPs on hepatic drug metabolism using rat and cellular models. These results suggest that the metabolism and elimination of drugs that are metabolized by CYP1A2 or CYP3A4 may be altered by an increase in AOPPs, and additional studies are required to determine the relationships between AOPPs and DMEs. Prospective clinical studies are needed to investigate the extent of the contribution of AOPPs to the pharmacokinetic changes related to various drugs.

Data availability

All data and models during the study appear in the submitted article. The online version of this article (https://doi.org/10.1038/s41374-021-00610-9) contains supplementary material, which is available to authorized users.
Author contributions Study design: XXY. Data acquisition: TRX, ZFL, XKW, XZ, HXF, and DNG. Data analysis and interpretation: TRX and ZFL. Paper writing: TRX and ZFL. Critical revision of the paper: XXY, TRX and ZFL. Obtained funding: XXY and TRX. All authors read and approved the final paper.

Funding This work was supported by research grants from the National Natural Science Foundation of China (NO. 81573681), Guangdong Science and Technology Program (NO. 2015B0202111006), Shenzhen Foundation of Science and Technology (NO. JCYJ20190814112205770), and Research Foundation of Shenzhen Hospital of Southern Medical University (NO. PY2021YM03).

Compliance with ethical standards

Ethics All animal studies were approved by the institutional Animal Experiment Committee of the Southern Medical University. We have provided the ethics statement in the chapter of animal model in method.

Conflict of interest The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Tonelli M, Wiebe N, Manns BJ, Klarenbach SW, James MT, Ravani P, et al. Comparison of the complexity of patients seen by different medical subspecialists in a Universal Health Care System. JAMA Netw Open. 2018. https://doi.org/10.1001/jamanetworkopen.2018.4852.
2. Lalande L, Charpiat B, Leboucher G, Tod M. Consequences of renal failure on non-renal clearance of drugs. Clin Pharmacokinet. 2014;53:521–32.
3. Ladda MA, Goralski KB. The effects of CCKD on cytochrome P450-mediated drug metabolism. Adv Chronic Kidney Dis. 2016;23:67–75.
4. Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12:326–32.
5. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, et al. Characterization of hepatic cytochrome p4503a activity in patients with end-stage renal disease. Clin Pharmacol Ther. 2003;73:427–34.
6. Yeung CK, Shen DD, Thummel KE, Himmelfarb J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int. 2014;85:522–8.
7. Furge LL, Guengerich FP. Cytochrome P450 enzymes in drug metabolism and chemical toxicology: an introduction. Biochem Mol Biol Educ. 2006;34:66–74.
8. Guengerich FP. Cytochrome P450 and chemical toxicity. Chem Rev. 2008;21:70–83.
9. Michaud J, Dubé P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 2005;144:1067–77.
10. Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci. 2008;108:157–63.
11. Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, et al. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. Am J Kidney Dis. 2015;65:574–82.
12. Tsujimoto M, Higuchi K, Shima D, Yokota H, Furukubo T, Izumi S, et al. Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro. J Pharm Pharmacol. 2010;62:133–8.
13. Tsujimoto M, Sugimoto S, Nagamoto M, Furukubo T, Izumi S, Yamakawa T, et al. Possibility of decrease in CYP1A2 function in patients with end-stage renal disease. Ther Apher Dial. 2014;18:174–80.
14. Witko-Sarsat V, Friedlander M, Capellère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304–13.
15. Selmeci L. Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome. Free Radic Res. 2011;45:115–23.
16. Liao CR, Wang SN, Zhu SY, Wang YQ, Li ZZ, Liu ZY, et al. Advanced oxidation protein products increase TNF-α and IL-1β expression in chondrocytes via NADPH oxidase 4 and accelerate cartilage degeneration in osteoarthritis progression. Redox Biol. 2019. https://doi.org/10.1016/j.redox.2019.101306.
17. Ye W, Zhong Z, Zhu S, Zheng S, Xiao J, Song S, et al. Advanced oxidation protein products induce catabolic effect through oxidant-dependent activation of NF-κB pathway in human chondrocyte. Int Immunopharmacol. 2016;39:149–57.
18. Saito T, Takahashi Y, Hashimoto H, Kamataki T. Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor kappa B-like element. J Biol Chem. 2001;276:38010–22.
19. Ghosh S. Regulation of inducible gene expression by the transcription factor NF-κB. Immunol Res. 1999;19:183–9.
20. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 1999;18:6867–74.
21. Liao CR, Wang SN, Zhu SY, Wang YQ, Li ZZ, Liu ZY, et al. Advanced oxidation protein products increase TNF-α and IL-1β expression in chondrocytes via NADPH oxidase 4 and accelerate cartilage degeneration in osteoarthritis progression. Redox Biol. 2019. https://doi.org/10.1016/j.redox.2019.101306.
22. Ye W, Zhong Z, Zhu S, Zheng S, Xiao J, Song S, et al. Advanced oxidation protein products induce catabolic effect through oxidant-dependent activation of NF-κB pathway in human chondrocyte. Int Immunopharmacol. 2016;39:149–57.
23. Mo L, Xiao X, Song S, Miao H, Liu S, Guo D, et al. Protective effect of Huang Gan formula in 5/6 nephrectomized rats by depressing the Wnt/β-catenin signaling pathway. Drug Des Devel Ther. 2015;9:2867–81.
24. Yan T, Gao S, Peng X, Shi J, Xie C, Li Q, et al. Significantly decreased and more variable expression of major CYPs and UGTs in liver microsomes prepared from HBV-positive human hepatocellular carcinoma and matched pericarcinomatous tissues determined using an isotope label-free UPLC-MS/MS method. Pharm Res. 2015;32:1141–57.
25. Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K, et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmaco Exp Ther. 2004;308:300–6.
25. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys. 1988;263:424–36.

26. Momper JD, Venkataramanan R, Nolin TD. Nonrenal drug clearance in CKD: searching for the path less traveled. Adv Chronic Kidney Dis. 2010;17:384–91.

27. Cao W, Hou FF, Nie J. AOPPs and the progression of kidney disease. Kidney Int Suppl. 2014;4:102–6.

28. Iwao Y, Anraku M, Hiraike M, Kawai K, Nakajou K, Kai T, et al. The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). Drug Metab Pharmacokinet. 2006;21:140–6.

29. Zhao Y, Zhang L, Ouyang X, Jiang Z, Xie Z, Fan L, et al. Advanced oxidation protein products play critical roles in liver diseases. Eur J Clin Invest. 2019. https://doi.org/10.1111/eci.13098.

30. Huang Z, Wang M, Liu L, Peng J, Guo C, Chen X, et al. Transcriptional Repression of CYP3A4 by Increased miR-200a-3p and miR-150-5p Promotes Steatosis in vitro. Front Genet. 2019. https://doi.org/10.3389/fgene.2019.00484.

31. Strojny B, Sawosz E, Grodzik M, Jaworski S, Szczepaniak J, Sosnowska M, et al. Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. Int J Nanomedicine. 2018;13:8561–75.

32. McGraw J, Cherney M, Bichler K, Gerhardt A, Nauman M. The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019;315:9–13.

33. Wang JC, Zhao Y, Chen SJ, Long J, Jia QQ, Zhai JD, et al. AOPPs induce MCP-1 expression by increasing ROS-mediated activation of the NF-κB pathway in rat mesangial cells: inhibition by sesquiterpene lactones. Cell Physiol Biochem. 2013;32:1867–77.

34. Zordoky BN, El-Kadi AO. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr Drug Metab. 2009;10:164–78.

35. Zheng S, Zhong ZM, Qin S, Chen GX, Wu Q, Zeng JH, et al. Advanced oxidation protein products induce inflammatory response in fibroblast-like synoviocytes through NADPH oxidase-dependent activation of NF-κB. Cell Physiol Biochem. 2013;32:972–85.

36. Oettinger CW, Bland LA, Oliver JC, Arduino MJ, McAllister SK, Favero MS. The effect of uremia on tumor necrosis factor-alpha release after an in vitro whole-blood endotoxin challenge. J Am Soc Nephrol. 1994;4:1890–5.

37. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 1993;44:707–15.